EMA Recommends Granting a Marketing Authorisation for Tarlatamab By Ogkologos - April 17, 2026 204 0 Facebook Twitter Google+ Pinterest WhatsApp It is indicated for the treatment of adult patients with extensive-stage SCLC Source RELATED ARTICLESMORE FROM AUTHOR Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism EMA Recommends Extension of Indications for Ponatinib Associated with a New Pharmaceutical Form and a New Strength MOST POPULAR Cross-Border Network of European Specialists Provides New Treatment Options For Women... June 17, 2024 Oncology Dietitians Don’t Usually Inquire About Food Insecurity in Cancer Patients,... February 12, 2022 37-Year-Old Mom Breaks American Marathon Record January 21, 2022 Tumors May Shed Protein to Create Barriers that Block Immune Cells December 10, 2021 Load more HOT NEWS FDA Grants Traditional Approval for Selpercatinib for Medullary Thyroid Cancer with... Large DFS Benefit from Adjuvant Cemiplimab Among Patients at High Risk... How My Cancer Diagnosis at Age 17 Changed My Perspective on... A Large Case-Control Study of Hodgkin Lymphoma Survivors Suggests a Dose-Response...
